Advances in Cancer Research
Academic Press
Published on 17. December 1992
311 pages
978-0-08-056242-1 (ISBN)
Description
Advances in Cancer Research
More details
Other editions
Additional editions
George F. Vande Woude | G. Klein
Advances in Cancer Research: v. 60
Book
11/1992
Academic Press
€71.92
Article exhausted; check different version
Persons
Content
- Front Cover
- Advances in Cancer Research, Volume 60
- Copyright Page
- Contents
- Contributors
- Chapter 1. Structural and Functional Diversity in the FGF Receptor Multigene Family
- I. Introduction
- II. The FGF Family of Polypeptide Mitogens
- III. Early Binding and Cross-Linking Studies of the FGF Receptor
- IV. Nomenclature of the FGF Receptor Genes
- V. Purification, cDNA Cloning, and Characterization of FGFR 1
- VI. Characterization of EFGR 2, FGFR 3, and FGFR 4
- VII. Multiple Forms of FGFR 1 and FGFR 2 Are Generated by Alternative Splicing
- VIII. Multiple Forms of FGFR 1
- IX. Multiple Forms of FGFR 2
- X. FGFR 3 and FGFR 4
- XI. Ligand Binding Specificities of the Cloned FGF Receptors
- XII. Alternative Splicing in the Third Ig Domain Is Important for Determining Ligand Binding Specificities
- XIII. Analogous Splice Variants from Different FGF Receptor Genes Encode Receptor Forms with Different Ligand Binding Specificities
- XIV. Regulation of FGF Receptor Expression
- XV. Cell- and Tissue-Specific Alternative Splicing of FGF Receptor mRNAs
- XVI. Differential, Tissue-Specific Expression of the Different ' FGF Receptor Genes
- XVII. The Drosophila FGF Receptor
- XVIII. FGF Receptor-Mediated Signal Transduction
- XIX. Concluding Remarks
- References
- Chapter 2. Protein Tyrosine Kinase Growth Factor Receptors and Their Ligands in Development, Differentiation, and Cancer
- I. Introduction
- II. Structure of Receptor Protein Tyrosine Kinases
- III. RTKs in Development
- IV. RTKs and Tumorigenesis
- V. Genetics and Cancer
- Reference
- Chapter 3. The Molecular and Genetic Characterization of Human Soft Tissue Tumors
- I. Introduction
- II. Tumor Etiology
- III. Genetic Susceptibility to Soft Tissue Tumors
- IV. Detection of ras Gene Activation
- V. Chromosomal Abnormalities
- VI. Tumor Suppressor Genes
- VII. Gene Amplification
- VIII. Predictors of Tumor Behavior
- IX. Molecular Cloning of Translocation Breakpoints
- X. Future Developments
- Reference
- Note Added in Proof
- Chapter 4. Genomic instability and Tumor Progression: Mechanistic Considerations
- I. Introduction
- II. Genomic Stability and Instability: Background and Implications
- III. Mechanisms of Genomic Stability and Instability
- IV. Quantitative Considerations
- V. Summary and Perspectives
- References
- Chapter 5. Function and Regulation of the Human Multidrug Resistance Gene
- I. The Multidrug Transporter as a Cause of Multidrug Resistance
- II. Regulation of Expression of mdr Genes
- III. Summary and Conclusions
- Reference
- Chapter 6. Relationship between MYC Oncogene Activation and MHC Class I Expression
- I. Introduction
- II. MHC Class I Expression and Cancer
- III. Modulation of MHC Class I Expression by Oncogences
- IV. Molecular Mechanism of MHC Class I Regulation by Oncogenes
- V. Biological Consequences of MHC Class I Downmodulation by Oncogenes
- VI. Concluding Remarks
- References
- Chapter 7. Immunosuppressive Factors in Human Cancer
- I. Introduction
- II. Immunosuppression in Cancer-Recent Evidence
- III. Immunosuppressive Factors Produced by Tumor Cells/Cell Lines
- IV. Well-Characterized Immunosuppressive Molecules
- V. Partially Characterized Immunosuppressive Factors
- VI. Immunosuppressive Factors in Sera and Effusions
- VII. Other Immunosuppressive Factors
- VIII. Concluding Remarks: Immunosuppressor or Growth-Regulatory Cytokines?
- References
- Chapter 8. Lysosomes, Lysosomal Enzymes, and Cancer
- I. Introduction
- II. Methods for Studying Lysosomes
- III. Lysosomal Enzyme Activity in Tumors
- IV. Lysosomes, Tumor Invasion. and Metastasis
- V. Lysosomes and Tumor Microenvironment
- VI. Lysosomes and Anticancer Therapy
- VII. Conclusion
- References
- Index
